rendering the current emetogenic
categories less suitable for delayed
CINV manifestations. 1
The main goal of CINV
prophylactic and therapeutic
approaches is to reduce the
complications associated with
nausea and vomiting and, at
the same time, allow patients
to maintain their optimal
chemotherapy treatment plans
without loss of efficacy due to
dose adjustments or delays of the
anticancer agents. 3
Inadequate management of
nausea and vomiting strongly
affects the effectiveness of
chemotherapy by delaying cycles
and requiring administration of
rescue antiemetic medications
and/or fluid therapy, potentially
leading to patient adherence
issues. In some cases, patients
may discontinue their treatments
as a result of severe CINV, which
could negatively affect survival
outcomes. Failure to prevent
and control CINV also intensifies
utilisation of health care resources
and can further increase the cost of
cancer treatments and the overall
burden to health care systems.
In support of prompt prophylactic
and therapeutic interventions for
CINV, a meta-analysis of studies
evaluating health-related quality
of life outcomes revealed that even
patients receiving moderately
emetogenic chemotherapy were
severely affected in their daily
activities by these side effects of
chemotherapy. In addition, an
analysis of data extracted from
health economics studies revealed
that direct costs (for example,
costs associated with antiemetic
hospitalpharmacyeurope.com | 2018 | 27